RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
For RA Patients, Functional Disability May Precede Diagnosis
Biologics May Prevent Cardiovascular Events in RA Patients
ABX464 in Phase 2a Trials for RA
Seronegative RA May Be on the Rise
Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes
Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares
Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
New Research Identifies Possible Preclinical Rheumatoid Arthritis Biomarkers
- 1
- 2
- 3
- …
- 24
- Next Page »